newdrugapprovals.org
Glenmark’s TRPA1 antagonist ‘GRC 17536’ shows positive data in a proof of concept study
MUMBAI, India, Sep 17, 2014 – Glenmark’s first in class TRPA1 antagonist, GRC 17536, has shown positive data in a Phase 2a proof of concept study in patients with painful diabeti…